MarketMoodz
Gilgamesh Withdraws Patent Challenge After AbbVie Deal
Gilgamesh Pharmaceuticals pulled its Post-Grant Review against Enveric's '276 patent in November 2025 after AbbVie filed to withdraw the petition. Enveric says the core claims remain uncontested, reducing near-term IP risk and potentially accelerating licensing discussions tied to GM-2505.
Key Takeaways
- Gilgamesh withdrew its Post-Grant Review against Enveric's '276 patent in November 2025 after AbbVie requested withdrawal.
- '276 patent covers halogenated psilocybin derivatives linked to Enveric's GM-2505 (bretisilocin).
- AbbVie agreed to acquire Gilgamesh's bretisilocin asset for up to $1.2 billion in 2025.
- Enveric says withdrawal resolves the proceeding and leaves the patent unchallenged, reducing IP risk.
- ENVB stock moved lower in premarket trading on the news (down about 1.45%).
People Involved
- No specific individuals mentioned
Entities Involved
- Enveric Biosciences Inc (ENVB)Owner of GM-2505 program and issuer of the contested '276 patent
- AbbVie Inc (ABBV)Buyer of Gilgamesh's bretisilocin asset; requested withdrawal of the petition
- Gilgamesh Pharmaceuticals IncAsset owner; participant in the PGR and in the AbbVie deal
MarketMoodz Analysis
For investors, the withdrawal removes a persistent IP risk around GM-2505 and the EB-003 program, potentially clearing the path for licensing discussions and boosting partner interest as a pharma acquirer shows appetite for psychedelic-based assets. The AbbVie-Gilgamesh deal backdrop adds strategic value to Enveric's IP moat by aligning major pharma with the asset class.
Historically, post-grant challenges in biotech/IP can delay collaborations and deprioritize licensing talks. The absence of ongoing challenges to the '276 patent may support a higher near-term valuation for Enveric, but progress on EB-003 data and regulatory milestones will determine the ultimate licensing trajectory and deal outcomes.
Watch for EB-003 clinical updates, news on formal licensing talks or partnerships tied to the '276 portfolio, and any further PTAB docket activity or company disclosures that could alter the IP-risk profile.
Source: Original Article